Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
Innate Pharma is set to co-host a scientific symposium titled 'Next Generation Immunotherapy Discoveries' with the Icahn School of Medicine at Mount Sinai on October 3, 2024. The event, part of Innate Pharma's 25th anniversary celebration, will be held in a hybrid format in New York City and online from 10:00 a.m. to 5:30 p.m. EDT.
The symposium will showcase the latest advances in immunotherapy, featuring presentations from key opinion leaders in the field. Participants will have the opportunity to engage with speakers during Q&A sessions. Prior to the symposium, Innate Pharma will host an Investor and Analyst Meeting from 8:30 a.m. to 9:30 a.m. EDT to provide an overview of the company's therapeutic innovations.
The event will include speakers from prestigious institutions such as Memorial Sloan Kettering Cancer Center, Harvard Medical School, and UCLA Jonsson Comprehensive Cancer Center, among others.
Innate Pharma co-organizzerà un simposio scientifico intitolato 'Scoperte nella Immunoterapia di Nuova Generazione' con la Icahn School of Medicine del Mount Sinai il 3 ottobre 2024. L'evento, che fa parte della celebrazione del 25° anniversario di Innate Pharma, si svolgerà in formato ibrido a New York City e online, dalle 10:00 alle 17:30 EDT.
Il simposio metterà in mostra i più recenti progressi nell'immunoterapia, con presentazioni da parte di leader d'opinione nel settore. I partecipanti avranno l'opportunità di interagire con i relatori durante le sessioni di domande e risposte. Prima del simposio, Innate Pharma ospiterà un Incontro con Investitori e Analisti dalle 8:30 alle 9:30 EDT per fornire una panoramica delle innovazioni terapeutiche dell'azienda.
L'evento includerà relatori provenienti da istituzioni prestigiose come il Memorial Sloan Kettering Cancer Center, la Harvard Medical School e il UCLA Jonsson Comprehensive Cancer Center, tra gli altri.
Innate Pharma coorganizará un simposio científico titulado 'Descubrimientos de Inmunoterapia de Nueva Generación' con la Icahn School of Medicine en Mount Sinai el 3 de octubre de 2024. El evento, parte de la celebración del 25º aniversario de Innate Pharma, se llevará a cabo en un formato híbrido en la ciudad de Nueva York y en línea, desde las 10:00 a.m. hasta las 5:30 p.m. EDT.
El simposio mostrará los últimos avances en inmunoterapia, con presentaciones de líderes de opinión en el campo. Los participantes tendrán la oportunidad de interactuar con los ponentes durante las sesiones de preguntas y respuestas. Antes del simposio, Innate Pharma organizará una Reunión con Inversores y Analistas de 8:30 a 9:30 a.m. EDT para proporcionar una visión general de las innovaciones terapéuticas de la empresa.
El evento contará con oradores de prestigiosas instituciones como el Memorial Sloan Kettering Cancer Center, la Harvard Medical School y el UCLA Jonsson Comprehensive Cancer Center, entre otros.
Innate Pharma는 '차세대 면역 요법 발견'이라는 제목의 과학 심포지엄을 마운트 시나이의 아이칸 의과대학과 공동 주최할 예정입니다. 이 행사는 2024년 10월 3일에 열리며, Innate Pharma의 25주년 기념 행사 일환으로, 뉴욕시와 온라인에서 하이브리드 형식으로 진행됩니다. 시간은 EDT 기준으로 오전 10시부터 오후 5시 30분까지입니다.
이번 심포지엄은 면역 요법의 최신 발전을 조명하며, 해당 분야의 핵심 의견 리더들이 프레젠테이션을 진행합니다. 참가자들은 질의응답 시간에 발표자들과 소통할 기회를 갖게 됩니다. 심포지엄에 앞서, Innate Pharma는 투자자 및 애널리스트 회의를 오전 8시 30분부터 9시 30분까지 EDT 기준으로 개최하여 회사의 치료 혁신에 대한 개요를 제공할 예정입니다.
이번 행사에는 메모리얼 슬론 케터링 암 센터, 하버드 의과 대학, UCLA 존슨 종합 암 센터 등 여러 저명한 기관의 연사들이 포함될 것입니다.
Innate Pharma co-organisera un symposium scientifique intitulé 'Découvertes en immunothérapie de nouvelle génération' avec l'Icahn School of Medicine au Mount Sinai le 3 octobre 2024. L'événement, qui fait partie de la célébration du 25ème anniversaire d'Innate Pharma, se déroulera sous un format hybride à New York et en ligne, de 10h00 à 17h30 EDT.
Le symposium mettra en avant les dernières avancées en immunothérapie, avec des présentations de leaders d'opinion dans le domaine. Les participants auront la possibilité d'échanger avec les intervenants lors des sessions de questions-réponses. Avant le symposium, Innate Pharma organisera une Réunion avec les Investisseurs et Analystes de 8h30 à 9h30 EDT pour fournir un aperçu des innovations thérapeutiques de l'entreprise.
L'événement comprendra des orateurs de prestigieuses institutions telles que le Memorial Sloan Kettering Cancer Center, la Harvard Medical School et le UCLA Jonsson Comprehensive Cancer Center, entre autres.
Innate Pharma wird am 3. Oktober 2024 ein wissenschaftliches Symposium mit dem Titel 'Entdeckungen in der Immuntherapie der nächsten Generation' in Zusammenarbeit mit der Icahn School of Medicine am Mount Sinai ausrichten. Die Veranstaltung, die Teil der Feierlichkeiten zum 25-jährigen Bestehen von Innate Pharma ist, findet in einem hybriden Format in New York City und online von 10:00 bis 17:30 Uhr EDT statt.
Das Symposium wird die neuesten Fortschritte in der Immuntherapie präsentieren und umfasst Beiträge von Meinungsführern auf diesem Gebiet. Die Teilnehmer haben die Möglichkeit, während der Frage-und-Antwort-Sitzungen mit den Referenten zu interagieren. Vor dem Symposium wird Innate Pharma ein Investor und Analysten Meeting von 8:30 bis 9:30 Uhr EDT veranstalten, um einen Überblick über die therapeutischen Innovationen des Unternehmens zu bieten.
Die Veranstaltung wird Redner von renommierten Einrichtungen wie dem Memorial Sloan Kettering Cancer Center, der Harvard Medical School und dem UCLA Jonsson Comprehensive Cancer Center umfassen.
- None.
- None.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will co-host with the Icahn School of Medicine at
This major scientific event, organized as part of Innate Pharma 25th anniversary, will highlight the latest and greatest advances in immunotherapy and feature key opinion leaders who will share their knowledge and expertise in immunotherapy. Participants will be able to interact with the speakers in a Q&A session after each presentation.
“Since its inception in 1999, Innate Pharma has been pioneering immuno-oncology, a field which has revolutionized cancer care. As we celebrate 25 years of innovation at Innate Pharma, this is an opportunity to look forward, not only at the broad and diversified pipeline that Innate has generated, but beyond at the next frontiers of immunotherapy. Leading scientists and clinicians will share their perspective at the Next Generation Immunotherapy Discoveries symposium to take place in
Confirmed speakers and chairs:
Speakers:
- Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center
-
Thomas Marron, Ph.D., Icahn School of Medicine at
Mount Sinai - Diane Mathis, Ph.D. Harvard Medical School
-
Miriam Merad, MD, Ph.D., Icahn School of Medicine at
Mount Sinai - Pierluigi Porcu, MD, Thomas Jefferson University
- Katy Rezvani MD, Ph.D., MD Anderson Cancer Center
- Antoni Ribas, MD, University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center
- Dimitri Skokos, Ph.D., Regeneron
- Eric Vivier, DVM, Ph.D., Innate Pharma and CIML
Chairs:
-
Dr. Amir Horowitz, Ph.D. from Icahn School of Medicine at
Mount Sinai - Dr. Joao Monteiro, MD, Ph.D., Nature Medicine
For the full program and registration form of “Next Generation Immunotherapy Discoveries” symposium, please click here.
Prior to the symposium, Innate Pharma will host an Investor and Analyst Meeting from 8:30 a.m. to 9:30 a.m. EDT to provide an overview of the Company's therapeutic innovations. If you would like to attend, please contact investors@innate-pharma.fr.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET® multi-specific NK cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.
Information about Innate Pharma shares
ISIN code
|
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240929070399/en/
For additional information, please contact:
Investors
Innate Pharma
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Source: Innate Pharma SA
FAQ
When and where is Innate Pharma's 'Next Generation Immunotherapy Discoveries' symposium taking place?
What is the purpose of Innate Pharma's (IPHA) upcoming scientific symposium?
Will there be an opportunity for investors to learn about Innate Pharma's (IPHA) therapeutic innovations?
Who are some of the confirmed speakers for Innate Pharma's (IPHA) immunotherapy symposium?
